|
1
|
Gibbs AR and Thunnissen FB: Histological
typing of lung and pleural tumours: Third edition. J Clin Pathol.
54:498–499. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Galateau-Salle F, Churg A, Roggli V and
Travis WD; World Health Organization Committee for Tumors of the
Pleura, : The 2015 World Health Organization classification of
tumors of the pleura: Advances since the 2004 classification. J
Thorac Oncol. 11:142–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hashimoto K, Okuma Y, Hosomi Y and Hishima
T: Malignant mesothelioma of the pleura with desmoplastic
histology: A case series and literature review. BMC Cancer.
16:7182016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leung AN, Müller NL and Miller RR: CT in
differential diagnosis of diffuse pleural disease. AJR Am J
Roentgenol. 154:487–492. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kawashima A and Libshitz HI: Malignant
pleural mesothelioma: CT manifestations in 50 cases. AJR Am J
Roentgenol. 155:965–969. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang ZJ, Reddy GP, Gotway MB, Higgins CB,
Jablons DM, Ramaswamy M, Hawkins RA and Webb WR: Malignant pleural
mesothelioma: Evaluation with CT, MR imaging, and PET.
Radiographics. 24:105–119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Manegold C, et al: Phase III study of pemetrexed in combination
with cisplatin versus cisplatin alone in patients with malignant
pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zauderer MG, Kass SL, Woo K, Sima CS,
Ginsberg MS and Krug LM: Vinorelbine and gemcitabine as second- or
third-line therapy for malignant pleural mesothelioma. Lung Cancer.
84:271–274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Christoph DC and Eberhardt WE: Systemic
treatment of malignant pleural mesothelioma: New agents in clinical
trials raise hope of relevant improvements. Curr Opin Oncol.
26:171–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sharma SV, Haber DA and Settleman J: Cell
line-based platforms to evaluate the therapeutic efficacy of
candidate anticancer agents. Nat Rev Cancer. 10:241–253. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iorio F, Knijnenburg TA, Vis DJ, Bignell
GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S,
Lightfoot H, et al: A landscape of pharmacogenomic interactions in
cancer. Cell. 166:740–754. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Teicher BA, Polley E, Kunkel M, Evans D,
Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, et
al: Sarcoma cell line screen of oncology drugs and investigational
agents identifies patterns associated with gene and microRNA
expression. Mol Cancer Ther. 14:2452–2462. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oey H, Daniels M, Relan V, Chee TM,
Davidson MR, Yang IA, Ellis JJ, Fong KM, Krause L and Bowman RV:
Whole-genome sequencing of human malignant mesothelioma tumours and
cell lines. Carcinogenesis. 40:724–734. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Relan V, Morrison L, Parsonson K, Clarke
BE, Duhig EE, Windsor MN, Matar KS, Naidoo R, Passmore L, McCaul E,
et al: Phenotypes and karyotypes of human malignant mesothelioma
cell lines. PLoS One. 8:e581322013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Conte N, Mason JC, Halmagyi C, Neuhauser
S, Mosaku A, Yordanova G, Chatzipli A, Begley DA, Krupke DM,
Parkinson H, et al: PDX Finder: A portal for patient-derived tumor
xenograft model discovery. Nucleic Acids Res. 47(D1): D1073–D1079.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoshimatsu Y, Noguchi R, Tsuchiya R, Kito
F, Sei A, Sugaya J, Nakagawa M, Yoshida A, Iwata S, Kawai A and
Kondo T: Establishment and characterization of NCC-CDS2-C1: A novel
patient-derived cell line of CIC-DUX4 sarcoma. Hum Cell.
33:427–436. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bairoch A: The cellosaurus, a cell-line
knowledge resource. J Biomol Tech. 29:25–38. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Capes-Davis A, Reid YA, Kline MC, Storts
DR, Strauss E, Dirks WG, Drexler HG, MacLeod RA, Sykes G, Kohara A,
et al: Match criteria for human cell line authentication: Where do
we draw the line? Int J Cancer. 132:2510–2519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Noguchi R, Yoshimatsu Y, Ono T, Sei A,
Hirabayashi K, Ozawa I, Kikuta K and Kondo T: Establishment and
characterization of NCC-PLPS1-C1, a novel patient-derived cell line
of pleomorphic liposarcoma. Hum Cell. 34:688–697. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Olshen AB, Venkatraman ES, Lucito R and
Wigler M: Circular binary segmentation for the analysis of
array-based DNA copy number data. Biostatistics. 5:557–572. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Venkatraman ES and Olshen AB: A faster
circular binary segmentation algorithm for the analysis of array
CGH data. Bioinformatics. 23:657–663. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Willenbrock H and Fridlyand J: A
comparison study: Applying segmentation to array CGH data for
downstream analyses. Bioinformatics. 21:4084–4091. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Forbes SA, Tang G, Bindal N, Bamford S,
Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, et al: COSMIC
(the catalogue of somatic mutations in cancer): A resource to
investigate acquired mutations in human cancer. Nucleic Acids Res
38 (Database Issue). D652–D657. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Billiau A, Edy VG, Heremans H, Van Damme
J, Desmyter J, Georgiades JA and De Somer P: Human interferon: Mass
production in a newly established cell line, MG-63. Antimicrob
Agents Chemother. 12:11–15. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sikkema AH, Diks SH, den Dunnen WF, ter
Elst A, Scherpen FJ, Hoving EW, Ruijtenbeek R, Boender PJ, de Wijn
R, Kamps WA, et al: Kinome profiling in pediatric brain tumors as a
new approach for target discovery. Cancer Res. 69:5987–5995. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hornbeck PV, Zhang B, Murray B, Kornhauser
JM, Latham V and Skrzypek E: PhosphoSitePlus, 2014: Mutations, PTMs
and recalibrations. Nucleic Acids Res 43 (Database Issue).
D512–D520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
UniProt Consortium: UniProt: A worldwide
hub of protein knowledge. Nucleic Acids Res. 47(D1): D506–D515.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Keshava Prasad TS, Goel R, Kandasamy K,
Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R,
Shafreen B, Venugopal A, et al: Human protein reference
database-2009 update. Nucleic Acids Res 37 (Database Issue).
D767–D772. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Meerbeeck JP, Baas P, Debruyne C,
Groen HJ, Manegold C, Ardizzoni A, Gridelli C, van Marck EA, Lentz
M and Giaccone G: A Phase II study of gemcitabine in patients with
malignant pleural mesothelioma. European organization for research
and treatment of cancer lung cancer cooperative group. Cancer.
85:2577–2582. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zucali PA, Ceresoli GL, Garassino I, De
Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto
Parra HJ and Santoro A: Gemcitabine and vinorelbine in
pemetrexed-pretreated patients with malignant pleural mesothelioma.
Cancer. 112:1555–1561. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zucali PA, Perrino M, Lorenzi E, Ceresoli
GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R,
Giordano L and Santoro A: Vinorelbine in pemetrexed-pretreated
patients with malignant pleural mesothelioma. Lung Cancer.
84:265–270. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Szulkin A, Nilsonne G, Mundt F, Wasik AM,
Souri P, Hjerpe A and Dobra K: Variation in drug sensitivity of
malignant mesothelioma cell lines with substantial effects of
selenite and bortezomib, highlights need for individualized
therapy. PLoS One. 8:e659032013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
O'Brien ME, Gaafar RM, Popat S, Grossi F,
Price A, Talbot DC, Cufer T, Ottensmeier C, Danson S, Pallis A, et
al: Phase II study of first-line bortezomib and cisplatin in
malignant pleural mesothelioma and prospective validation of
progression free survival rate as a primary end-point for
mesothelioma clinical trials (European organisation for research
and treatment of cancer 08052). Eur J Cancer. 49:2815–2822. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fennell DA, McDowell C, Busacca S, Webb G,
Moulton B, Cakana A, O'Byrne KJ, Meerbeeck JV, Donnellan P,
McCaffrey J and Baas P: Phase II clinical trial of first or
second-line treatment with bortezomib in patients with malignant
pleural mesothelioma. J Thorac Oncol. 7:1466–1470. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang CC, Han CS, Yue XF, Shen CM, Wang
SW, Wu FG and Xu B: Cytotoxicity and sister chromatid exchanges
induced in vitro by six anticancer drugs developed in the People's
Republic of China. J Natl Cancer Inst. 71:841–847. 1983.PubMed/NCBI
|
|
37
|
Kantarjian HM, Keating MJ, Walters RS,
Koller CA, McCredie KB and Freireich EJ: Phase II study of low-dose
continuous infusion homoharringtonine in refractory acute
myelogenous leukemia. Cancer. 63:813–817. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Quintás-Cardama A, Kantarjian H,
Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A,
Ladie N, Verstovsek S and Cortes J: Phase I/II study of
subcutaneous homoharringtonine in patients with chronic myeloid
leukemia who have failed prior therapy. Cancer. 109:248–255. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Friedberg JW, Sharman J, Sweetenham J,
Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S,
Sinha R, Leonard JP, et al: Inhibition of Syk with fostamatinib
disodium has significant clinical activity in non-Hodgkin lymphoma
and chronic lymphocytic leukemia. Blood. 115:2578–2585. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tsao AS, He D, Saigal B, Liu S, Lee JJ,
Bakkannagari S, Ordonez NG, Hong WK, Wistuba I and Johnson FM:
Inhibition of c-Src expression and activation in malignant pleural
mesothelioma tissues leads to apoptosis, cell cycle arrest, and
decreased migration and invasion. Mol Cancer Ther. 6:1962–1972.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu D, Liang SQ, Yang H, Bruggmann R,
Berezowska S, Yang Z, Marti TM, Hall SRR, Gao Y, Kocher GJ, et al:
CRISPR screening identifies WEE1 as a combination target for
standard chemotherapy in malignant pleural mesothelioma. Mol Cancer
Ther. 19:661–672. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dorai T, Kobayashi H, Holland JF and
Ohnuma T: Modulation of platelet-derived growth factor-beta mRNA
expression and cell growth in a human mesothelioma cell line by a
hammerhead ribozyme. Mol Pharmacol. 46:437–444. 1994.PubMed/NCBI
|
|
43
|
Langerak AW, Dirks RP and Versnel MA:
Splicing of the platelet-derived-growth-factor A-chain mRNA in
human malignant mesothelioma cell lines and regulation of its
expression. Eur J Biochem. 208:589–596. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Melaiu O, Catalano C, De Santi C,
Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M,
Guazzelli A, Boldrini L, et al: Inhibition of the platelet-derived
growth factor receptor beta (PDGFRB) using gene silencing,
crenolanib besylate, or imatinib mesylate hampers the malignant
phenotype of mesothelioma cell lines. Genes Cancer. 8:438–452.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Edgar R, Domrachev M and Lash AE: Gene
expression omnibus: NCBI gene expression and hybridization array
data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
|
